Improving the Quality of Two Lives by Treating Obesity

QR Code

Improving the Quality of Two Lives by Treating Obesity

<b>Background and Clinical Significance:</b> Kidney transplantation remains the most effective method of renal replacement therapy. Living donor transplantation offers several advantages—reduced cardiovascular risk, better graft survival, and preemptive intervention. However, donor obesi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Norbert Nagy, Patrícia Kleinová, Martin Jozef Péč, Matej Samoš, Ivana Dedinská
Format:	Article
Language:	English
Published:	MDPI AG 2025-06-01
Series:	Reports
Subjects:	obesity treatment living kidney donation GLP-1 receptor agonist
Online Access:	https://www.mdpi.com/2571-841X/8/2/85
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
by: Giulia Migliorisi, et al.
Published: (2025-07-01)

The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists in Polycystic Ovary Syndrome: A Narrative Review
by: Kamil Turlej, et al.
Published: (2025-07-01)

Role of physical activity in GLP-1 receptor agonist therapy for obesity treatment
by: Łukasz Zdziebkowski, et al.
Published: (2025-07-01)

Revisiting the role of novel weight management medications and bariatric surgery
by: LIANG Hui
Published: (2025-06-01)

Efficacy and Safety of Tirzepatide for Weight Management in Non-Diabetic Obese Individuals: A Narrative Review
by: Mohammed Sallam, et al.
Published: (2025-04-01)

Barriers to glucagon-like peptide-1 agonists used for obesity management among the general population in Tabuk City, Saudi Arabia, and their relation to smoking cessation and antidepressants
by: Amirah Alhowiti, et al.
Published: (2025-07-01)

Pulmonary artery pressure trajectories in heart failure patients treated with GLP‐1 receptor agonists
by: Haoran Jiang, et al.
Published: (2025-08-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Evolving Insights into Pathogenesis, Progression, and Personalized Treatment Approaches
by: Paweł Kukiełka, et al.
Published: (2025-07-01)

The Impact and Safety of GLP‐1 Agents and Breast Cancer
by: Kayla Parsons, et al.
Published: (2025-06-01)

Addressing weight loss management in obese gout patients: guidance for future trials
by: Robin Christensen, et al.
Published: (2024-11-01)

Weight Loss Effects of Once-Weekly Semaglutide 2.4 mg in Adults with and Without Type 2 Diabetes: A Systematic Review and Meta-Analysis
by: Boram Hong, et al.
Published: (2025-07-01)

Physiology and pharmacology of glucagon-like peptide-1 receptor
by: D. V. Kurkin, et al.
Published: (2024-01-01)

Suboptimal physician adherence to evidence‐based guidelines for managing cardiorenal comorbidities in diabetes care: A retrospective single‐center study in Taiwan
by: Zong‐Yu Shen, et al.
Published: (2025-08-01)

Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies
by: Vincenzo Trapanese, et al.
Published: (2025-05-01)

Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society
by: Dariush Mozaffarian, et al.
Published: (2025-09-01)

Liver function effects of SGLT2 inhibitor and GLP‐1 receptor agonist combination treatment in patients with type 2 diabetes (post hoc analysis of RECAP study)
by: Daisuke Tsuriya, et al.
Published: (2025-07-01)

Could Increased Glp1r Expression via Sitagliptin in the GLP-1/GLP-1 Receptor Axis in the DietInduced Obesity Rat Model be Important in Liver Metabolism?
by: Cem Horozoğlu, et al.
Published: (2024-12-01)

Promising areas of pharmacotherapy for obesity
by: M. A. Druzhilov, et al.
Published: (2021-04-01)

Oral Small-Molecule GLP-1 Receptor Agonists: Mechanistic Insights and Emerging Therapeutic Strategies
by: Héctor Iván Saldívar-Cerón, et al.
Published: (2025-06-01)

Neuromyelitis optica spectrum disorder-like presentation following semaglutide therapy: A case report
by: Moneera O. Aldraihem, et al.
Published: (2025-09-01)

GLP-1 and Its Role in Glycogen Production: A Narrative Review
by: Joseph Lotosky, et al.
Published: (2025-06-01)

Living Kidney Donation Practices in Europe: A Survey of DESCaRTES and EKITA Transplantation Working Groups
by: Marco van Londen, et al.
Published: (2025-07-01)

Developing an Adult Living Donor Liver Transplant Program in Western Europe: The Rotterdam Experience
by: Alicia Jane Chorley, et al.
Published: (2025-07-01)

Hormonal modulation, mitochondria and Alzheimer’s prevention: the role of GLP-1 agonists and estrogens
by: Fernando Lizcano, et al.
Published: (2025-06-01)

The role of glucagon-like peptide-1 receptor agonists in the correction of immune and metabolic disorders in women with reproductive dysfunction
by: N. D. Kozhukhov, et al.
Published: (2020-04-01)

Compare the Decrease in Visceral Adipose Tissue in People with Obesity and Prediabetes vs. Obesity and Type 2 Diabetes Treated with Liraglutide
by: Rosa Nayely Hernández-Flandes, et al.
Published: (2025-07-01)

Efficacy and Safety of Liraglutide in Adolescents Aged 12–15 Years with Obesity: a Prospective 24-week Observational
by: Olga P. Kovtun, et al.
Published: (2025-05-01)

Efficacy and Safety of Glucagon‐Like Peptide‐1 Agonists for Psychiatric Symptoms: A Systematic Review
by: Shakila Meshkat, et al.
Published: (2025-07-01)

Comparative Effectiveness of Bariatric Surgery Versus GLP‐1 Receptor Agonists in Reducing the Risk of New‐Onset of NASH: A Retrospective Multinational Cohort Study From North America and Europe
by: Abdallah Hussein, et al.
Published: (2025-07-01)

Real-World Analysis of Short-Term Effectiveness of Oral Semaglutide: Impact on Glycometabolic Control and Cardiovascular Risk
by: Sara Palazzi, et al.
Published: (2025-06-01)

Analysis of implications of organ donation on living donors in southeastern Iran: A qualitative study
by: R. S. Bahador, et al.
Published: (2022-04-01)

EVALUATION, SELECTION AND PREPARATION OF LIVING DONOR FOR PARTIAL LIVER TRANSPLANTATION IN CHILDREN
by: S. V. Gautier, et al.
Published: (2015-04-01)

Effect of GLP-1 Receptor Agonists (Liraglutide) on Glycemic Parameters and Circulating miRNA Expression in Type 2 Diabetes Mellitus
by: Aqeel Meer AL-ZAMILY
Published: (2025-06-01)

Multiomics insight into the role of glucagon‐like peptide‐1 receptor agonists in heart failure
by: Yuhang Tao, et al.
Published: (2025-08-01)

Mechanism of glucagon-like peptide-1 receptor agonist in the treatment of obesity and food addiction
by: LIU Luyao, LI Linwei, WANG Chen, DI Jianzhong
Published: (2025-06-01)

The efficacy of liraglutide-based drugs on the model of induced metabolic syndrome in experimental animals
by: A. A. Andreev-Andrievsky, et al.
Published: (2025-08-01)

Abdominal Massage Decreases Food Intake and Body Weight in High-Fat Diet-Induced Obese Rats Through Upregulating GPR41/GPR43-PYY/GLP-1 Axis
by: Ma F, et al.
Published: (2025-05-01)

Comparative analysis of pharmacokinetic parameters, bioequivalence, safety, tolerability and immunogenicity of semaglutide-based drug for the treatment of obesity
by: A. S. Ametov, et al.
Published: (2025-03-01)

Symptomatic Adverse Events and Quality of Life Related to Incretin-Based Medicines for Obesity: A Systematic Review Involving >400,000 Subjects
by: Robert F. Kushner, et al.
Published: (2025-04-01)

Laparoscopic and robotic hepatectomy in living liver donors. Current state and prospects
by: K. O. Semash
Published: (2025-03-01)